SMS Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 23, 2026, titled "Press Release".
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals reported strong FY26 results with PAT growing 48% YoY to ₹102 crore, driven by backward integration and favorable product mix. Revenue from operations grew 13% to ₹886.87 crore, supported by growth across key APIs. EBITDA margin expanded 155 bps YoY to 19%, demonstrating improved operational efficiency. The company attributed margin expansion to structural cost advantages from backward integration rather than temporary pricing benefits. Q4FY26 showed some sequential softness with revenue at ₹237.95 crore vs ₹248.20 crore in Q4FY25, reflecting ongoing portfolio optimization. The ₹280 crore capex programme remains on track for FY27 completion. The Board recommended a final dividend of ₹0.40 per share.
Strong profitability growth with margin expansion signals operational strength and successful execution of backward integration strategy. The company guiding for over 15% revenue growth and 20% EBITDA margins in FY27 is positive for shareholders.